Abstract

Study design: Retrospective descriptive study. Aim: To describe the spectrum of clinical, neurological and MRI features and final visual outcome in myelin oligodendrocyte glycoprotein (MOG) antibody-positive optic neuritis. Method: Retrospective study from 2016 to 2022. Results: Study included 16patients; 9/16(56.25%)females, with mean(+SD) age38.62(+11.85) years. Bilateral involvement in14/16(87.5%), pain4/16(25%), disc edema7/16(43.75%), disc pallor 12/16(75%). Vision loss at presentation: mild 2/16(12.5%), moderate 1/16(6.25%) and severe 13/16(81.25%); final visual acuity was mild 9/15(60%), moderate 2/15(15.33%) and severe 4/15(26.66%). Neurological deficit None in8/16(50%), transverse myelitis 6/16(37.5%) and hemiparesis 2/16(12.5%). MRI optic nerve hyperintensity in 4/16(25%). Conclusion: MOG antibody-positive optic neuritis is characterized by severe bilateral disease, with optic disc changes. However, the final visual outcome is good despite very poor vision at presentation.

Full Text